Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ADCV02
- Development stage
- Preclinical
- Lead developer
- Ever Supreme Bio-Technology
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
01
Overview
ADCV02 is an investigational autologous dendritic cell vaccine being developed by Ever Supreme Bio Technology. As a therapeutic cancer vaccine and cell therapy, it is designed to induce tumor-specific immune responses by utilizing the patient's own dendritic cells to present antigens to the immune system, thereby activating T cells to recognize and attack malignant cells. While Ever Supreme's related candidate ADCV01 is specifically targeted toward Glioblastoma Multiforme (GBM), the specific molecular targets and primary disease indications for ADCV02 have not been publicly disclosed. It represents a key component of the company's immune cell therapy platform, which focuses on regenerative medicine and oncology.
- Other names
- ADCV02 dendritic cell vaccineADCV-02 dendritic cell vaccineADCV 02 dendritic cell vaccine
Beyond the preview
Go deeper on ADCV02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ADCV02.